These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 31855256)

  • 21. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer.
    Zhao L; Wang J; Li H; Che J; Cao B
    Oncotarget; 2016 May; 7(22):33418-28. PubMed ID: 27072579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Network Meta-analysis of First-Line Systemic Treatment for Patients With Metastatic Colorectal Cancer.
    Xu S; Sak A; Erol YB
    Cancer Control; 2021; 28():10732748211033497. PubMed ID: 34554888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis.
    Botrel TE; Clark O; Clark L; Paladini L; Faleiros E; Pegoretti B
    Lung Cancer; 2011 Oct; 74(1):89-97. PubMed ID: 21377753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer.
    Petrioli R; Francini E; Cherri S; Torre P; Fiaschi AI; Miano ST; Marrelli D; Rovello F; Francini G
    Clin Colorectal Cancer; 2018 Dec; 17(4):e663-e669. PubMed ID: 30153975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis.
    Ma H; Wu X; Tao M; Tang N; Li Y; Zhang X; Zhou Q
    Medicine (Baltimore); 2019 Dec; 98(50):e18227. PubMed ID: 31852082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018).
    Takashima A; Hamaguchi T; Mizusawa J; Nagashima F; Ando M; Ojima H; Denda T; Watanabe J; Shinozaki K; Baba H; Asayama M; Hasegawa S; Masuishi T; Nakata K; Tsukamoto S; Katayama H; Nakamura K; Fukuda H; Kanemitsu Y; Shimada Y;
    J Clin Oncol; 2024 Nov; 42(33):3967-3976. PubMed ID: 39186709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different doses of bevacizumab in combination with chemotherapy for advanced colorectal cancer: a meta-analysis and Bayesian analysis.
    Deng J; Zeng X; Hu W; Yue T; Luo Z; Zeng L; Li P; Chen J
    Int J Colorectal Dis; 2023 Jun; 38(1):164. PubMed ID: 37289304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis.
    Kaveh S; Ebrahimi P; Rezapour A; Mozafari M; Sayehmiri K
    Int J Clin Pharm; 2019 Feb; 41(1):30-41. PubMed ID: 30610548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT).
    Qi L; Ding L; Wang S; Zhong Y; Zhao D; Gao L; Wang W; Lv P; Xu Y; Wang S
    Oncotarget; 2016 Oct; 7(42):69002-69013. PubMed ID: 27458167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis.
    Mastrantoni L; Beccia V; Caira G; Trovato G; Calegari MA; Basso M; Salvatore L; Pozzo C; Tortora G; Bria E; Orlandi A
    Crit Rev Oncol Hematol; 2023 Nov; 191():104106. PubMed ID: 37659764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis.
    Zhou M; Yu P; Qu X; Liu Y; Zhang J
    PLoS One; 2013; 8(12):e81858. PubMed ID: 24324725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis.
    Berry SR; Cosby R; Asmis T; Chan K; Hammad N; Krzyzanowska MK;
    Ann Oncol; 2015 Mar; 26(3):477-85. PubMed ID: 25057174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials.
    Liu X; Liu X; Qiao T; Chen W; Yuan S
    Onco Targets Ther; 2016; 9():3771-81. PubMed ID: 27445484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Who will benefit more from maintenance therapy of metastatic colorectal cancer?
    Zhou M; Fu L; Zhang J
    Oncotarget; 2018 Feb; 9(15):12479-12486. PubMed ID: 29552327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
    Hu W; Xu WS; Liao XF; He HJ
    Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
    JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.